Company Name, Ticker, Competitors, else..

Nanoviricides inc (NYSE: NNVC)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Nanoviricides Inc 's

Name: Nanoviricides Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NNVC Sales vs. its Competitors Q3 2026

Comparing the current results to its competitors, Nanoviricides Inc reported Revenue decrease in the 3 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.85 %, recorded in the same quarter.

• List of NNVC Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Nanoviricides inc , slower than the average decrease reported by the company's competitors of -41.77 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -41.77 %

<< NNVC Stock Performance Comparisons

Nanoviricides Inc 's Comment on Competition and Industry Peers

The company utilizes patents, trade secrets, internal expertise, technological innovations, and third-party agreements to maintain its competitive position. It pursues patent protection in the United States and internationally, including filing international PCT patent applications for coronavirus drug candidates. The company has licensed its COVID-19 drug candidates NV-CoV-2 and NV-CoV-2-R to Karveer Meditech Private Limited, India (KMPL), which is responsible for further development and clinical trials in India. The competitive landscape includes companies such as Karveer Meditech Private Limited, Pfizer, and TheraCour. Approved COVID-19 treatments mentioned include remdesivir, an antiviral drug requiring repeated infusions with limited clinical effectiveness, and Pfizer's oral Paxlovid, a combination of nirmatrelvir and ritonavir tablets.

<< See the full list of NNVC competitors

*Market share is calculated based on total revenue.

NNVC's Stock Performance relative to its Competitors

Publicly Traded Peers of Nanoviricides inc

Tiziana Life Sciences Ltd
Share Performance

-22.07%

This Quarter

Tiziana Life Sciences Ltd

Profile

Tiziana Life Sciences Ltd's business model focuses on the development and commercialization of innovative therapeutics in the field of immunology and oncology.

More about Tiziana Life Sciences Ltd's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ -18.431 mill.

Lunai Bioworks Inc
Share Performance

-66.56%

This Year

Lunai Bioworks Inc

Profile

Lunai Bioworks is a pre-clinical biotechnology company focused on developing cell, gene, and immunotherapy treatments for cancer.

More about Lunai Bioworks Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 8.123 mill.	$ 0.021 mill.	$ -128.284 mill.

Arcus Biosciences Inc
Share Performance

+156.71%

One Year

Arcus Biosciences Inc

Profile

Arcus Biosciences Inc is a biotechnology company that focuses on developing immuno-oncology therapies. Their business model revolves around discovering and developing novel small molecule and antibody therapeutics to target various cancer indications. They aim to combine their extensive understanding of the immune system with innovative technology platforms to create effective treatments for patients with cancer.

More about Arcus Biosciences Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 3,664.466 mill.	$ 117.000 mill.	$ -460.000 mill.

Aixcrypto Holdings Inc
Share Performance

-60.09%

One Year

Aixcrypto Holdings Inc

Profile

AIxCrypto Holdings develops software focused on tokenizing real-world assets and deploying embodied artificial intelligence.

More about Aixcrypto Holdings Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 14.006 mill.	$ - mill.	$ -13.172 mill.

Pyxis Oncology Inc
Share Performance

+20.06%

Over The Past 5 Days

Pyxis Oncology Inc

Profile

Pyxis Oncology Inc is a biotechnology company focused on developing innovative cancer therapies. Their business model revolves around leveraging novel insights into the immune system to develop a pipeline of potential immunotherapies for cancer treatment. Pyxis Oncology aims to collaborate with strategic partners to advance their therapies through preclinical and clinical development, ultimately aiming to improve patient outcomes in the field of oncology.

More about Pyxis Oncology Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 248.927 mill.	$ - mill.	$ -88.727 mill.

149 more competitors available

Sources: Nanoviricides inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Tuesday, September 8, 2026 10:50 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Nanoviricides inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.